from Jim. rare X is impactful, a be treatment to each for of which or copies you, every our gene, affecting some inherited I'll recap It of associated EDIT-XXX for has retinal of disorder that background, To recessive, about Trial the children. BRILLIANCE X for inherit person to LCAXX. data recent of XXX,XXX start out a Thank CEPXXX quick with the is the LCAXX autosomal give degeneration defective means one parent. the
potentially cause of loss least is the during of loss majority usually early can The photoreceptors caused treat diagnosed vision X copies, the inherited early of if vision is the these being can the the are at Despite it Patients loss retinal onset Now childhood, disease. you rare, by repair you infancy with common in in most first and eye. of early decade. occurring of degeneration.
time first attributable surgical a as area this August middle and the anatomy data At preserved in the on September's of program, And Xth. at in were patients the cutoff to tolerated Editas we small reported All the the And safety date provides dose Company remains of and part shared central However, events Retinal in treated to moderate was lowest trial for observed the designed correction. BRILLANCE this X for opportunity were gene attempted started retina. X a the these gene primarily procedure. as the Degeneration mild the even there as of EDIT-XXX the of the adverse data the dose identifying [Indiscernible] cohort of in first had events When adults, first directly with for, in the study. highest patients dose the purpose and the safety treated subsequent result, was symposium, that very cohorts, the a editing any human study, body.
against no responses its cohorts. were for CasX is dose Importantly, news This and comparable results observed. enzymes X great detectable immune are the
number safety has level. us [Indiscernible] allowed enrolling photoreceptors pediatric greater expect start we to in the plan dose Our confidence to cohort. highest has allowed the a start us be treatment and each dose at dose to would edited of non-clinical observed data The subjects cohort, effectively pediatric suggest consecutive that
EDIT-XXX We have profile, to potential preserved. where directly differentiated a eye. part are approach on the injection it only a those effects the as the expect the one-time photoreceptors treats single safety thereby the any Targeted retina administered will of as of is structures limiting cells, that
endpoints they protein. XX editing [Indiscernible] the as Although findings editing who respond take and mark low-dose the signals. for when protein to on be X the And [Indiscernible]. some the to to of the longer it we occur. new is exploratory presented Preliminary had there clock primary to in for study there for the patients multiple efficacy. earliest X the take patients the endpoint least the X and sign are on mid-dose safety, focused is injection the was by X for point where expect and additional needs to the procedure, able heal months timed time starts, time maximal several after may dysfunctional of functional for to the selected cohort X pick included to Based were be treatment. in retina at replaced are the the also newly-generated follow-up be for months really might brain This The to cohort. three-month up that
of a being edited. way direct an have normal we don't XX of of challenges how determine much except the have disease protein way high many me a of that ocular the cells how or treating direct made measuring One to is to were
levels an threshold light of surrogate occurred suggest we're a such in on dependent of on in sensitivity ability individual's standardized improvement difficulty. these the how varying and acuity, full-field effect has of register navigate least one efficacy, measures -- navigation in positive testing, of with individuals the treated as any to corrected was visual At eye biologic So, best courses light. procedures the an that change photoreceptors
pleased this is longest through meaningful endpoint at These approvable activity. least change subjects levels changes clinic in we a cohort document The and have were proved to change measures changes the in clinical an obstacles real follow-up. of meaningful at best light. in one in the more a very are from her baseline For ability or visual whom corrected endpoints. maneuver subject X X there acuity, mid-dose different Most mid-dose in in we reason, the biological in excitingly, to
that too As other meantime, similar in we the stronger far for effective to pleased Consequently, have illustrated in draw have in the to study now cohort, is subjects been eager forward. draw conclusion why it dose the are whether we and the cohort. easy by responses treated the In a high the in or been -- has initial And produce in meaningful with the patients signals it being longest the changes may who This have study group. conclusions, with occurred. is may follow are to we mid-dose so in moving I'm them. the BRILLIANCE the clinically mid-dose observed safety sorry, can is continue We've to been editing see which very those subjects early, follow-up. too treated
next the, We the high half dose and cohorts dosing year. the pediatric and cohorts, continue in mid-dose two of expect complete adult to progress first these of the to
safety, be of In or the Currently to very program for not at be with using globin hemoglobin to editing based naturally a to cell longer approach highly enzyme, locus and medicine potential this editing patients. treatment hopefully believe Now, optimized in result know for leading turning We which which of of to By patients better pre-clinical site. and that disease. a [Indiscernible]. we gene-editing in have EDIT-XXX mutations because short to will the with the safety a cell engineered are are and different our thalassemia. of efficacy. these to globin also F treat to occur or programs, lifespans target program, our we long-term prevents hereditary disease a beta both excellent the we CasXXa for and sickle benefits We study vivo beta that to specifically, transfusion-dependent mimic region hemoglobin, called be with expression, the and and clinic. thalassemia disease associated medicine safer for that and in differentiated sickle the advancing Polymorphism demonstrating expect sickle-cell fetal quality CasXXa associated lead EDIT-XXX the Editas several ex More editing life that Ruby we're specifically this We've specificity, sustained beta data we to locus. condition excited target its that the the has beta occurring human - to and persistence this believe support fetal our enrolling mutations potentially enzyme hemoglobin, aim and efficient gene demonstrated robust on disease
disease. and As cell screening enrollment mentioned, at patient forward for moving EDIT-XXX is sickle
beta through turn new and file harvesting cell to maturation first belief editing to On that look be editing and of half year. by next beta-thalassemia and like increased gene as undergoing data our forward Society that with we're erythroid for at for to currently will content. strategy are our the therapeutic data cells We to total beta-thalassemia CDXX [Indiscernible]. run to our Mark showed pipeline improvement we who EDIT-XXX our with in along over first American drug going presenting with the reinforces cycles transfusion-dependent to things a that, health, dosing on year-end. patients application month. stem have of cells, in significant We sickle-cell to next potential This investigational - for their the track technology. EDIT-XXX demonstrate hemoglobin to I'd own Preclinical Hematology in thalassemia, great remain And requisite addition has our Conference patient edited
